|Publication number||US3541208 A|
|Publication date||Nov 17, 1970|
|Filing date||Sep 10, 1968|
|Priority date||Sep 10, 1968|
|Publication number||US 3541208 A, US 3541208A, US-A-3541208, US3541208 A, US3541208A|
|Inventors||Clay J Dann Sr|
|Original Assignee||Arcom Holding Corp|
|Export Citation||BiBTeX, EndNote, RefMan|
|Non-Patent Citations (1), Referenced by (7), Classifications (5)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent O RELIEF OF ARTHRITIS WITH A SOLUBLE SILI- CATE AND A SOLUBLE POLYPHOSPHATE Clay J. Dann, Sr., Secaucus, N.J., assignor to Arcom Holding Corporation, Old Tappan, N]. No Drawing. Filed Sept. 10, 1968, Ser. No. 758,680 Int. Cl. A61k 27/00 US. Cl. 424-128 4 Claims ABSTRACT OF THE DISCLOSURE This invention relates to a method of relieving arthritis, and particularly osteoarthritis by administering to a patient suffering from the same a solution of a soluble silicate, particularly sodium silicate plus a soluble polyphosphate, particularly sodium polyphosphate, which has the effect of preventing the deposition of calcium on the bone surface and eventually of removing the calcification of the arthritis.
BACKGROUND OF THE INVENTION Arthritis is a well known debilitating condition which mainly takes two forms, one of which is known as osteoarthritis. While the cause of osteoarthritis is not known, the condition involves enlargement of the joint with apparent rough calcium deposit being formed thereon. The treatments in common usage mainly rely on pain killers and on cortisone and cortisone derivatives. Attempts have been made to decalcify the enlarged excess calcium deposit, but such attempts have in general met with failure.
SUMMARY OF THE INVENTION It is accordingly a primary object of the present invention to provide a method of treatment of osteoarthritis which causes decalcification of the excess calcium deposited in the joint, prevents additional calcium from depositing, and eventually results in the return of the joint to normal size, smoothness and hardness.
It is another object of the present invention to provide a safe method of relieving osteoarthritis and particularly of causing decalcification of the calcium deposited at the joints with safety.
Other objects and advantages of the present invention will be apparent from a further reading of the specification and of the appended claims.
With the above and other objects in view, the present invention mainly comprises administering an effective amount of an aqueous solution of a physiologically compatible water soluble silicate and of a physiologically compatible water soluble polyphosphate.
While the invention is not meant to be limited to any specific theory as to how or why this composition is effective in relieving osteoarthritis, the following theory is given in the hope that it will aid in further research in this field. It is believed that the combination of the silicate and the polyphosphate causes the calcium at the calcified area of the osteoarthritis to become sequestered therewith so that this decalcified area looses some of the calcium and thereby becomes smaller. It also prevents calcium from depositing at the joint. In causing decalcification this apparently first occurs at the ridges or rough surfaces on the joint so that the joint not only eventually returns to normal size but the bone surface becomes smoother and harder.
The preferred silicates are sodium or potassium silicate. Most preferred is sodium silicate because of ready availability and economy. Likewise, in the case of the polyphosphate, the preferred polyphosphates are potassium polyphosphate and sodium polyphosphate, with sodium 3,541,208 Patented Nov. 17, 1970 polyphosphate being most preferred. In the case of treatment of patients with high blood pressure it may be advisable to use potassium silicate and potassium polyphosphate in place of the corresponding sodium silicate and sodium polyphosphate. For purposes of simplicity of discussion, in the following, reference will generally be had to sodium silicate and sodium polyphosphate. It is to be understood, however, that potassium silicate and/ or potassium polyphosphate may be substituted or used in admixture with sodium silicate and sodium polyphosphate.
It is preferred to prepare a concentrated solution of the sodium silicate and sodium polyphosphate and to use the same as the base composition for the treatment according to this invention. The simplest mode of administration is then to distribute a few drops of the concentrated solution in an ingestible liquid such as water and to drink the liquid. Of course, it is also possible to take, for example, a teaspoon of the concentrated solution and to wash it down with a liquid such as water. The composition is fully effective upon oral administration.
The amounts of the silicate and the polyphosphate in the concentrated solution can vary within relatively wide limits. Preferably, the concentration of sodium silicate in the solution is between about 15 and 45% by weight, most preferably about 25-35% by weight. The concentration of the sodium polyphosphate in the solution is preferably between about 25% and 55% by weight; most preferably between about 35% and 45% by weight.
The dosage of the above solution, administered orally, is between about 0.15 cc.1.5 cc. per day. The preferred dosage is about 0.45-0.75 cc. per day.
Thus, in dry weight the daily dosage can vary from about 2.25 mg.-67.5 mg. of the silicate and about 3.75 mg.-82.5 mg. of the polyphosphate.
As indicated above, the preferred mode of administration is to take about 3 drops (0.15 cc.) of the concentrated solution, add the same to a glass of water and to drink the water.
DESCRIPTION OF PREFERRED EMBODIMENTS The following examples are given to further illustrate the present invention. The scope of the invention is not, however, meant to be limited to the specific details of the examples.
Example 1 A concentrated solution of about 28% sodium silicate and 38% sodium polyphosphate in water is prepared. This solution is administered to a patient suffering from osteoarthritis by adding 3 drops (0.15 cc.) of the solution to a glass of water, this amount being taken by the patient three times a day. Several weeks are required before relief of the osteoarthritis occurs.
Example 2 A solution is prepared of about 15% sodium silicate and about 50% sodium polyphosphate. This solution is administered in the same manner and for the same purpose as in Example 1.
Example 3 of sodium and potassium silicate and about 2555% by weight of a physiologically compatible water soluble polyphosphate selected from the group consisting of sodium and potassium polyphosphate.
2. Method according to claim 1 wherein said silicate is sodium silicate and said polyphosphate is sodium polyphosphate.
3. Method according to claim 1 wherein the amount of silicate administered is between about 2.25 mg. and 67.5 mg. per day and the amount of polyphosphate is between about 3.75 mg. and 82.5 mg. per day.
4. Method according to claim 1 wherein an aqueous Chem. Abst., 32, p. 3902 (1938).
STANLEY J. FRIEDMAN, Primary Examiner U.S. Cl. X.R. 424184
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5171583 *||Oct 17, 1989||Dec 15, 1992||The Regents Of The University Of California||Treatment of osteoporosis using potassium bicarbonate|
|US5932252 *||Jan 23, 1995||Aug 3, 1999||The Regents Of The University Of California||Method and composition for treatment of osteoporosis|
|US6027737 *||Oct 27, 1994||Feb 22, 2000||The Regents Of The University Of California||Treatment for osteoporosis using potassium salts|
|US20100173010 *||Dec 21, 2004||Jul 8, 2010||Universitá Degli Studi Di Siena||Polymetaphosphate based formulations for therapy of microcrystalline arthropathies|
|WO1990004402A1 *||Oct 20, 1989||May 3, 1990||The Regents Of The University Of California||Treatment of osteoporosis|
|WO2005060978A2 *||Dec 21, 2004||Jul 7, 2005||Universitá Degli Studi Di Siena||Polymetaphosphate based formulations for therapy of microcrystalline arthropathies|
|WO2005060978A3 *||Dec 21, 2004||Aug 4, 2005||Alberto Campana||Polymetaphosphate based formulations for therapy of microcrystalline arthropathies|
|U.S. Classification||424/601, 424/677|